A Prospective Diagnostic Belief Updating Study to verIfy the Utility of BioEP in First Seizure Clinics.

Epilepsy Clinical Trial

— PRISTINE  

Official title:

Utility of a Computational Biomarker (BioEP) in Supporting Clinicians' Decision Making in Patients Presenting to an Adult Epilepsy Service First-seizure Clinic: A Prospective Diagnostic Belief Updating Study.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05764252
• Other study ID #: NNBioEP001
• Status: Recruiting
• Phase: N/A
• Start date: August 23, 2023
• Est. completion date: May 2025

Study information

• Verified date: April 2024
• Source: Neuronostics Ltd
• Contact: Milaana A Mainstone
• Phone: +44 (0)117 457 2292
• Email: m.mainstone[@]neuronostics.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this belief updating study is to assess the utility of BioEP as a complementary support tool in aiding clinical decision making in adults in first seizure clinics. The main outcomes we shall measure are:

• Clinicians' perception of seizure probability.

• Clinicians' decision to recommend commencing or deferring ASM (anti-seizure medications)

• Clinicians' decision to refer for additional investigations/services.

Participants will consent to have their EEG (that is taken at their routine care) to be used in the study. There is not extra burden to the participants taking part in the study.

Description:

The accurate diagnosis and prognosis of epilepsy represents a significant unmet medical need. Due to the unpredictable nature of seizures, epilepsy is difficult to diagnose and treat. In the United Kingdom (UK), 125,000 people per annum are referred to first seizure clinics with suspected epilepsy of which 40,000 receive a confirmed diagnosis of epilepsy. Although diagnosing a patient with epilepsy is a clinical decision, clinicians often look towards diagnostic tests (such as electroencephalograms - EEGs) to support their decision-making process. At present, in the absence of observable epileptiform abnormalities (abnormal wave forms strongly associated with epilepsy on EEG, there are no clinically robust markers of epilepsy. Mathematical models provide a powerful and useful tool with which to identify and understand biological mechanisms that may lead to the risk of having seizures. By combining mathematical and computational techniques, Neuronostics have developed a biomarker called BioEP. Using properties in the background and clinically non contributary EEG, the investigators have demonstrated in retrospective, multi-site phase I and phase II studies sufficient evidence that could support clinicians to make more informed diagnostic decisions that investigators hope will lead to better and faster decisions about patients' diagnosis and treatment. The investigators will now conduct a prospective single site diagnostic belief updating study to examine the utility of BioEP in supporting clinicians' decision making a clinical setting in the NHS. The investigators will do this by inviting adults to take part who are suspected of having a first seizure and who will attend a first seizure clinic run by a Consultant Nurse for the Epilepsies (CNE) at the Royal Wolverhampton NHS trust. As part of the patients diagnostic work up, patients will have an EEG performed, the investigators will then apply BioEP to the patients EEG to derive a "risk score". This risk score will be presented to the CNE, who may then decide to combine it with the clinical history and clinical test information to help the CNE make decisions about patients' diagnosis and treatment.

The CNE will first rate the probability that the patient has experienced an epileptic seizure and probability of recurrence based on the clinical history and standard EEG (and any other standard tests ordered). A second assessment of this probability will be made after the CNE subsequently receives the BioEP risk score and report to quantify the updating of belief (that the patient has an increased seizure risk) and assess the utility of BioEP as a diagnostic decision support tool.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 88
• Est. completion date: May 2025
• Est. primary completion date: May 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult (age 18 and above) presenting with first suspected seizure(s)

• Able to give informed consent

• Patient receives EEG following clinicians' decision to refer for an EEG based on clinical history and seizure description taken during first seizure clinic.

Exclusion Criteria:

• Participants unable to tolerate an EEG test so no EEG data was gathered

• Participants with a known hepatic/renal encephalopathy

• Participants that upon history taking have a clear clinical diagnosis of a physical condition other than epilepsy (e.g., vasovagal syncope)

Related Conditions & MeSH terms

• Epilepsy
• Seizures

Intervention

Device:
• BioEP
All patient's EEG will have the BioEP score conducted on it

Locations

Country	Name	City	State
United Kingdom	Phil Tittensor	Wolverhampton

Sponsors (1)

Lead Sponsor	Collaborator
Neuronostics Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinicians' perception of seizure probability in a 2 step process, using a 7-category scale and a 100-mm visual analogue scale	The clinician rates the probability that the patient will experience another epileptic seizure before and after the presentation of the BioEP score (updating beliefs). Using the clinician's ratings, we will impute the implicit individual likelihood ratios - the factor changes in the perceived odds of the patient experiencing another epileptic seizure based on the updated beliefs in the face of new evidence (the BioEP score)	1 day
Primary	Number of additional patient's investigations/services	Clinicians' decision-making over time will be explored. When patients present multiple times over a period, more clinical information is gathered and thus clinicians' perception of the probability of a seizure may change as evidence increases. The influence of multiple presentations and investigations shall be considered and reported descriptively. Any additional EEGs performed in the 1-year follow up period shall be analysed by our methods. The risk score will be presented to the CNE, who may then decide to combine it with any new emerging clinical history and clinical test information to help the CNE make any further decisions about patients' diagnosis and treatment.	1 year
Primary	Number of Clinicians' decisions to recommend commencing or deferring anti-seizure medications (ASM)	Clinicians' decision-making over time will be explored. The decisions to recommend commencing or deferring ASMs will be recorded.	1 year